Sudan Loganathan
Stock Analyst at Stephens
(4.18)
# 1,512
Out of 4,587 analysts
35
Total ratings
61.8%
Success rate
21.4%
Average return
Main Sectors:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Rated: Buy | $8 → $5 | $1.11 | +350.45% | 3 | Jun 4, 2026 | |
| PVLA Palvella Therapeutics | Initiated Coverage: Buy | $220 | $150.19 | +46.48% | 1 | May 11, 2026 | |
| IMNM Immunome | Rated: Buy | $33 → $30 | $23.08 | +29.98% | 3 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $110 → $100 | $107.01 | -6.55% | 3 | Mar 2, 2026 | |
| ARVN Arvinas | Maintained: Buy | $15 → $18 | $8.30 | +116.87% | 4 | Feb 25, 2026 | |
| APGE Apogee Therapeutics | Initiated Coverage: Buy | $95 | $134.30 | -29.26% | 1 | Dec 17, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $13 → $8 | $2.87 | +178.75% | 2 | Nov 24, 2025 | |
| CADL Candel Therapeutics | Initiated Coverage: Buy | $15 | $9.87 | +51.98% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Upgraded: Buy | $4 → $6 | $3.66 | +63.93% | 2 | Sep 15, 2025 | |
| FTH Faeth Therapeutics | Maintained: Buy | $5 → $35 | $28.82 | n/a | 2 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $29 → $60 | $55.97 | n/a | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $30 | $23.58 | n/a | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $5 | $0.837 | n/a | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $9.91 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $36.40 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $25 | $4.01 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $12.04 | n/a | 1 | May 13, 2024 |
ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.11
Upside: +350.45%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $150.19
Upside: +46.48%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $23.08
Upside: +29.98%
Kymera Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: $110 → $100
Current: $107.01
Upside: -6.55%
Arvinas
Feb 25, 2026
Maintained: Buy
Price Target: $15 → $18
Current: $8.30
Upside: +116.87%
Apogee Therapeutics
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $95
Current: $134.30
Upside: -29.26%
Pyxis Oncology
Nov 24, 2025
Maintained: Buy
Price Target: $13 → $8
Current: $2.87
Upside: +178.75%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $9.87
Upside: +51.98%
C4 Therapeutics
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $3.66
Upside: +63.93%
Faeth Therapeutics
Jun 30, 2025
Maintained: Buy
Price Target: $5 → $35
Current: $28.82
Upside: n/a
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $55.97
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $20 → $30
Current: $23.58
Upside: n/a
Nov 19, 2024
Reiterated: Buy
Price Target: $25 → $5
Current: $0.837
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $15
Current: $9.91
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $36.40
Upside: n/a
Nov 7, 2024
Initiated Coverage: Hold
Price Target: $25
Current: $4.01
Upside: n/a
May 13, 2024
Rated: Buy
Price Target: $25
Current: $12.04
Upside: n/a